Actively Recruiting
Determining the Mechanisms of Loss of CAR T Cell Persistence
Led by University College, London · Updated on 2024-05-23
50
Participants Needed
3
Research Sites
110 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
A prospective observational study of pediatric and young adult acute lymphoblastic leukaemia (ALL) patients treated with CD19 chimeric antigen receptor T-cells (CAR-T cells). The study will examine changes in CAR-T persistence over time and causal factors.
CONDITIONS
Official Title
Determining the Mechanisms of Loss of CAR T Cell Persistence
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Children and young adults aged 25 years or younger with relapsed or refractory acute lymphoblastic leukemia (ALL)
- Planned to receive licensed CD19-targeted CAR-T cell treatment (Tisagenlecleucel)
- Provided written informed consent
You will not qualify if you...
- Receiving an alternate CD19-directed CAR T-cell product as part of another clinical trial
- Unable to adhere to the study protocol as judged by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Great Ormond Street Hospital
London, United Kingdom
Actively Recruiting
2
University College London Hospital
London, United Kingdom
Actively Recruiting
3
Royal Manchester Children's Hospital
Manchester, United Kingdom
Actively Recruiting
Research Team
C
CARPERS Trial Manager
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here